Change of cancer and pericancerous tissue induced by inflammation, IL-6/TGF-beta crosstalk, in biliary tract cancers.
Project/Area Number |
24592024
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Research Institute, Osaka Medical Center for Cancer and Cardiovascular Disaeses (2014) Osaka University (2012-2013) |
Principal Investigator |
KOBAYASHI Shogo 地方独立行政法人大阪府立病院機構大阪府立成人病センター(研究所), その他部局等, その他 (30452436)
|
Co-Investigator(Kenkyū-buntansha) |
WADA Hiroshi 大阪大学, 医学系研究科, 助教 (00572554)
NAGANO Hiroaki 山口大学, 医学系研究科, 教授 (10294050)
MARUBASHI Shigeru 大阪大学, 医学系研究科, 助教 (20362725)
KAWAMOTO Koichi 大阪大学, 医学系研究科, 助教 (30432470)
EGUCHI Hidetoshi 大阪大学, 医学系研究科, 助教 (90542118)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 胆道癌 / 炎症性サイトカイン / 化学療法抵抗性 / 癌間質 / IL-6 / TGF-beta / 上皮間葉系転換 |
Outline of Final Research Achievements |
We revealed IL-6 / TGF-β crosstalk induced by inflammation in biliary tract cancers. This crosstalk induced Epithelial-Mesenchymal Transition (EMT) and chemo-resistance in cancer cells and invasion front of resected specimen, via SMAD4. There was possibility that this resistance might be removed by regulation of SMAD4 or Histone. Meanwhile, this resistance induced co-resistance for the other anti-cancer drugs via DNA repair system and population of stem cells; however, radiation therapy regulated this chemo-resistance. Taken together, chemo-resistance was noted at invasion front via inflammation (crosstalk) and chemo-radiation would be effective for this invasion front and it would be helpful for advanced surgical resection.
|
Report
(4 results)
Research Products
(43 results)
-
[Journal Article] BRCA/Fanconi Anemia Pathway Implicates Chemo-resistance to Gemcitabine in Biliary Tract Cancer.2015
Author(s)
Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.
-
Journal Title
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Intrahepatic cholangiocarcinoma in a worker at an offset color proof-printing company: An autopsy case report.2015
Author(s)
Tomimaru Y, Kobayashi S, Wada H, Hama N, Kawamoto K, Eguchi H, Kira T, Morii E, Doki Y, Mori M, Nagano H.
-
Journal Title
Hepatol Res
Volume: 45
Pages: 488-93
Related Report
Peer Reviewed
-
[Journal Article] Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma.2014
Author(s)
Takeda Y, Nakamori S, Eguchi H, Kobayashi S, Marubashi S, Tanemura M, Konishi K, Yoshioka Y, Umeshita K, Mori M, Doki Y, Nagano H.
-
Journal Title
Jpn J Clin Oncol.
Volume: 44
Pages: 1172-80
Related Report
Peer Reviewed
-
[Journal Article] Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer.2014
Author(s)
Nakashima S, Kobayashi S, Sakai D, Tomokuni A, Tomimaru Y, Hama N, Wada H, Kawamoto K, Marubashi S, Eguchi H, Matsuura N, Doki Y, Mori M, Nagano H.
-
Journal Title
J Surg Oncol
Volume: 110
Pages: 1016-22
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy2014
Author(s)
Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T.
-
Journal Title
Cancer Chemother Pharmacol.
Volume: 74
Pages: 699-709
Related Report
Peer Reviewed
-
[Journal Article] Reprogramming Using microRNA-302 Improves Drug Sensitivity in Hepatocellular Carcinoma Cells.2014
Author(s)
Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, Kawamoto K, Eguchi H, Konno M, Ishii H, Umeshita K, Doki Y, Mori M.
-
Journal Title
Ann Surg Oncol
Volume: 21
Pages: 591-600
Related Report
Peer Reviewed
-
[Journal Article] Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy2014
Author(s)
Toyoda M, Ajiki T, Fujiwara Y, Nagano H, Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, Tsuji A, Kaihara S, Ikoma H, Takemura S, Toyokawa H, Terajima H, Morita S, Ioka T
-
Journal Title
Cancer Chemother Pharmacol
Volume: 73
Pages: 1295-301
Related Report
Peer Reviewed
-
[Journal Article] A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.2014
Author(s)
Eguchi H, Nagano H, Kobayashi S, Kawamoto K, Wada H, Hama N, Tomimaru Y, Akita H, Sakai D, Satoh T, Kudo T, Isohashi F, Mori M, Doki Y.
-
Journal Title
Cancer Chemother Pharmacol
Volume: 73
Pages: 309-15
Related Report
Peer Reviewed
-
-
-
[Journal Article] Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer.2013
Author(s)
Kishimoto T, Eguchi H, Nagano H, Kobayashi S, Akita H, Hama N, Wada H, Kawamoto K, Tomokuni A, Tomimaru Y, Umeshita K, Doki Y, Mori M.
-
Journal Title
Cancer Sci
Volume: 104
Issue: 12
Pages: 1626-1631
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Inflammation-associated cytokines of biliary tract cancer induced chemo-resistance and therapeutic implications2014
Author(s)
Shogo Kobayashi, Hiroaki Nagano, Daisaku Yamada, Hideshi Ishii, Yoshito Tomimaru, Naoki Hama, Hiroshi Wada, Koichi Kawamoto, Hidetoshi Eguchi, Yuichiro Doki, and Masaki Mori.
Organizer
ASCO-GI
Place of Presentation
San Francisco, CA, USA
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-